Collection 3 (Sep 2022 - Aug 2023) Articles

Articles
Individualized therapy in statin intolerance: the key to success
Banach M, Cannon CP, Paneni F, et al.
Journal:
Eur Heart J

First published: October 18, 2022 DOI: 10.1093/eurheartj/ehac556
View
- Share
Articles
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees
Kronenberg F, Mora S, Stroes ESG
Journal:
Curr Opin Lipidol

First published: October 17, 2022 DOI: 10.1097/MOL.0000000000000855
View
- Share
Articles
Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease
Nissen SE, Wolski K, Cho L, et al.
Journal:
Open Heart

First published: October 17, 2022 DOI: 10.1136/openhrt-2022-002060
View
- Share
Articles
EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis: Meta-Analysis of Prospective Imaging Trials
Sheppard JP, Lakshmanan S, Dahal S, et al.
Journal:
JACC Cardiovasc Imaging

First published: October 15, 2022 DOI: 10.1016/j.jcmg.2022.04.014
View
- Share
Articles
World Heart Federation Cholesterol Roadmap 2022
Ray KK, Ference BA, Séverin T, et al.
Journal:
Global Heart

First published: October 14, 2022 DOI: 10.5334/gh.1154
View
- Share
Articles
Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes
Lacaze P, Bakshi A, Riaz M, et al.
Journal:
J Am Coll Cardiol

First published: October 4, 2022 DOI: 10.1016/j.jacc.2022.07.027
View
- Share
Articles
Lp(a): Are Antithrombotic Therapies the Key to Event Reduction?
Devesa A, Ibanez B, Fuster V
Journal:
J Am Coll Cardiol

First published: October 4, 2022 DOI: 10.1016/j.jacc.2022.08.722
View
- Share
Articles
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT
Santos RD, Ruzza A, Hovingh GK, et al.
Journal:
Lancet Diabetes Endocrinol

First published: October 1, 2022 DOI: 10.1016/S2213-8587(22)00221-2
View
- Share
Articles
Impact of variants of uncertain significance of LDL receptor on phenotypes of familial hypercholesterolemia
Tada H, Kojima N, Yamagami K, et al.
Journal:
J Clin Lipidol

First published: September 30, 2022 DOI: 10.1016/j.jacl.2022.09.007
View
- Share
Articles
Projected Impact of Treatment Intensification with Satin, Ezetimibe, and Statin plus Ezetimibe Fixed-Dose Combination on MACE Across Six Countries
Farnier M, Santos RD, Cosin-Sales J, et al.
Journal:
Eur J Prev Cardiol

First published: September 22, 2022 DOI: 10.1093/eurjpc/zwac214
View
- Share
Articles
Early identification and treatment of women’s cardiovascular risk factors prevents cardiovascular disease, saves lives, and protects future generations: Policy recommendations and take action plan utilizing policy levers
Ivey SL, Hanley HR, Taylor C, et al.
Journal:
Clin Cardiol

First published: September 20, 2022 DOI: 10.1002/clc.23921
View
- Share
Articles
Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA)
Chevli PA, Islam T, Pokharel Y, et al.
Journal:
J Clin Lipidol

First published: September 19, 2022 DOI: 10.1016/j.jacl.2022.09.005
View
- Share

1 … 5 6 7 8

Collection 3 (Sep 2022 - Aug 2023) Articles

Articles

Individualized therapy in statin intolerance: the key to success

Banach M, Cannon CP, Paneni F, et al.

Articles

Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees

Kronenberg F, Mora S, Stroes ESG

Articles

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease

Nissen SE, Wolski K, Cho L, et al.

Articles

EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis: Meta-Analysis of Prospective Imaging Trials

Sheppard JP, Lakshmanan S, Dahal S, et al.

Articles

World Heart Federation Cholesterol Roadmap 2022

Ray KK, Ference BA, Séverin T, et al.

Articles

Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes

Lacaze P, Bakshi A, Riaz M, et al.

Articles

Lp(a): Are Antithrombotic Therapies the Key to Event Reduction?

Devesa A, Ibanez B, Fuster V

Articles

Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT

Santos RD, Ruzza A, Hovingh GK, et al.

Articles

Impact of variants of uncertain significance of LDL receptor on phenotypes of familial hypercholesterolemia

Tada H, Kojima N, Yamagami K, et al.

Articles

Projected Impact of Treatment Intensification with Satin, Ezetimibe, and Statin plus Ezetimibe Fixed-Dose Combination on MACE Across Six Countries

Farnier M, Santos RD, Cosin-Sales J, et al.

Articles

Early identification and treatment of women’s cardiovascular risk factors prevents cardiovascular disease, saves lives, and protects future generations: Policy recommendations and take action plan utilizing policy levers

Ivey SL, Hanley HR, Taylor C, et al.

Articles

Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA)

Chevli PA, Islam T, Pokharel Y, et al.

Articles

Individualized therapy in statin intolerance: the key to success

Banach M, Cannon CP, Paneni F, et al.

Share

Articles

Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees

Kronenberg F, Mora S, Stroes ESG

Share

Articles

Lipoprotein(a) levels in a global population with established atherosclerotic cardiovascular disease

Nissen SE, Wolski K, Cho L, et al.

Share

Articles

EPA Versus Mixed EPA/DHA Plus Statin for Coronary Atherosclerosis: Meta-Analysis of Prospective Imaging Trials

Sheppard JP, Lakshmanan S, Dahal S, et al.

Share

Articles

World Heart Federation Cholesterol Roadmap 2022

Ray KK, Ference BA, Séverin T, et al.

Share

Articles

Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes

Lacaze P, Bakshi A, Riaz M, et al.

Share

Articles

Lp(a): Are Antithrombotic Therapies the Key to Event Reduction?

Devesa A, Ibanez B, Fuster V

Share

Articles

Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT

Santos RD, Ruzza A, Hovingh GK, et al.

Share

Articles

Impact of variants of uncertain significance of LDL receptor on phenotypes of familial hypercholesterolemia

Tada H, Kojima N, Yamagami K, et al.

Share

Articles

Projected Impact of Treatment Intensification with Satin, Ezetimibe, and Statin plus Ezetimibe Fixed-Dose Combination on MACE Across Six Countries

Farnier M, Santos RD, Cosin-Sales J, et al.

Share

Articles

Early identification and treatment of women’s cardiovascular risk factors prevents cardiovascular disease, saves lives, and protects future generations: Policy recommendations and take action plan utilizing policy levers

Ivey SL, Hanley HR, Taylor C, et al.

Share

Articles

Association between remnant lipoprotein cholesterol, high-sensitivity C-reactive protein, and risk of atherosclerotic cardiovascular disease events in the Multi-Ethnic Study of Atherosclerosis (MESA)

Chevli PA, Islam T, Pokharel Y, et al.

Share